The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

Scientists mapped where drugs bind inside the body, cell by cell, to better understand benefits and side effects.

Curis, Inc. , a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into a ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Researchers at University of California San Diego School of Medicine have led the first clinical trial in the world to show ...

For patients with Waldenström macroglobulinemia (WM), transitioning from ibrutinib (Imbruvica) to zanubrutinib (Brukinsa) may offer comparable clinical outcomes, as suggested by interim data from a ...

The therapy is a highly advanced form of radiation therapy that uses charged particles in the form of a proton that that gets ...

According to the World Health Organization, each year cervical cancer impacts approximately 600,000 women throughout the ...

Italian investigators sought to determine if combining R-CHOP plus ibrutinib followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC ...

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...